PEPGEN INC. Increase (Decrease) in Accrued Liabilities
PEPGEN INC. (PEPG) reported Increase (Decrease) in Accrued Liabilities of -$3.99 million for the 6-month period ending 2026-06-30, per its 10-Q filed 2026-08-06.
Financial Statements › Cash Flow › Operating Activities
us-gaap:IncreaseDecreaseInAccruedLiabilities · last filed 2026-08-06
- PEPGEN INC. increase (decrease) in accrued liabilities for the quarter ending 2026-06-30 was -$465.00K.
- PEPGEN INC. increase (decrease) in accrued liabilities for the quarter ending 2026-03-31 was -$3.53M, a 230.06% decline year-over-year.
- PEPGEN INC. increase (decrease) in accrued liabilities for the quarter ending 2025-12-31 was $255.00K, a 93.76% decline year-over-year.
- PEPGEN INC. increase (decrease) in accrued liabilities for the quarter ending 2025-09-30 was -$4.02M.
- PEPGEN INC. increase (decrease) in accrued liabilities for fiscal 2025 was -$3.27M.
- PEPGEN INC. increase (decrease) in accrued liabilities for fiscal 2024 was -$1.66M, a 216.95% decline from fiscal 2023.
- PEPGEN INC. increase (decrease) in accrued liabilities for fiscal 2023 was $1.42M, a 74.29% decline from fiscal 2022.
- PEPGEN INC. increase (decrease) in accrued liabilities for fiscal 2022 was $5.53M, a 18.91% decline from fiscal 2021.
| Period end | Increase (Decrease) in Accrued Liabilities 3 month | Increase (Decrease) in Accrued Liabilities 6 month | Increase (Decrease) in Accrued Liabilities 9 month | Increase (Decrease) in Accrued Liabilities 12 month |
|---|---|---|---|---|
| 2026-06-30 | -$465.00K derived: 10-Q 6 month − 10-Q 3 month · filed 2026-08-06 | -$3.99M 10-Q · filed 2026-08-06 | -$3.74M derived: sum of 3 quarters · filed 2026-08-06 | -$7.75M derived: sum of 4 quarters · filed 2026-08-06 |
| 2026-03-31 | -$3.53M 10-Q · filed 2026-05-12 | -$3.27M derived: sum of 2 quarters · filed 2026-05-12 | -$7.29M derived: sum of 3 quarters · filed 2026-05-12 | -$9.51M derived: sum of 4 quarters · filed 2026-08-06 |
| 2025-12-31 | $255.00K derived: 10-K 12 month − 10-Q 9 month · filed 2026-03-04 | -$3.76M derived: sum of 2 quarters · filed 2026-03-04 | -$5.98M derived: sum of 3 quarters · filed 2026-08-06 | -$3.27M 10-K · filed 2026-03-04 |
| 2025-09-30 | -$4.02M derived: 10-Q 9 month − 10-Q 6 month · filed 2025-11-12 | -$6.23M derived: sum of 2 quarters · filed 2026-08-06 | -$3.52M 10-Q · filed 2025-11-12 | $564.00K derived: sum of 4 quarters · filed 2026-08-06 |
| 2025-06-30 | -$2.21M derived: 10-Q 6 month − 10-Q 3 month · filed 2026-08-06 | $496.00K 10-Q · filed 2026-08-06 | $4.58M derived: sum of 3 quarters · filed 2026-08-06 | $1.10M derived: sum of 4 quarters · filed 2026-08-06 |
| 2025-03-31 | $2.71M 10-Q · filed 2026-05-12 | $6.80M derived: sum of 2 quarters · filed 2026-05-12 | $3.31M derived: sum of 3 quarters · filed 2026-05-12 | $7.81M derived: sum of 4 quarters · filed 2026-05-12 |
| 2024-12-31 | $4.09M derived: 10-K 12 month − 10-Q 9 month · filed 2026-03-04 | $600.00K derived: sum of 2 quarters · filed 2026-03-04 | $5.10M derived: sum of 3 quarters · filed 2026-03-04 | -$1.66M 10-K · filed 2026-03-04 |
| 2024-09-30 | -$3.49M derived: 10-Q 9 month − 10-Q 6 month · filed 2025-11-12 | $1.01M derived: sum of 2 quarters · filed 2025-11-12 | -$5.75M 10-Q · filed 2025-11-12 | -$6.31M derived: sum of 4 quarters · filed 2025-11-12 |
| 2024-06-30 | $4.50M derived: 10-Q 6 month − 10-Q 3 month · filed 2025-08-07 | -$2.26M 10-Q · filed 2025-08-07 | -$2.83M derived: sum of 3 quarters · filed 2025-08-07 | -$390.00K derived: sum of 4 quarters · filed 2025-08-07 |
| 2024-03-31 | -$6.76M 10-Q · filed 2025-05-08 | -$7.33M derived: sum of 2 quarters · filed 2025-05-08 | -$4.89M derived: sum of 3 quarters · filed 2025-05-08 | -$5.51M derived: sum of 4 quarters · filed 2025-05-08 |
| 2023-12-31 | -$563.00K derived: 10-K 12 month − 10-Q 9 month · filed 2025-02-24 | $1.87M derived: sum of 2 quarters · filed 2025-02-24 | $1.26M derived: sum of 3 quarters · filed 2025-02-24 | $1.42M 10-K · filed 2025-02-24 |
| 2023-09-30 | $2.44M derived: 10-Q 9 month − 10-Q 6 month · filed 2024-11-07 | $1.82M derived: sum of 2 quarters · filed 2024-11-07 | $1.99M 10-Q · filed 2024-11-07 | $4.04M derived: sum of 4 quarters · filed 2024-11-07 |
| 2023-06-30 | -$617.00K derived: 10-Q 6 month − 10-Q 3 month · filed 2024-08-08 | -$451.00K 10-Q · filed 2024-08-08 | $1.60M derived: sum of 3 quarters · filed 2024-08-08 | -$2.85M derived: sum of 4 quarters · filed 2024-08-08 |
| 2023-03-31 | $166.00K 10-Q · filed 2024-05-14 | $2.22M derived: sum of 2 quarters · filed 2024-05-14 | -$2.23M derived: sum of 3 quarters · filed 2024-05-14 | -$755.00K derived: sum of 4 quarters · filed 2024-05-14 |
| 2022-12-31 | $2.05M derived: 10-K/A 12 month − 10-Q 9 month · filed 2024-03-29 | -$2.40M derived: sum of 2 quarters · filed 2024-03-29 | -$921.00K derived: sum of 3 quarters · filed 2024-03-29 | $5.53M 10-K/A · filed 2024-03-29 |
| 2022-09-30 | -$4.45M derived: 10-Q 9 month − 10-Q 6 month · filed 2023-11-08 | -$2.97M derived: sum of 2 quarters · filed 2023-11-08 | $3.48M 10-Q · filed 2023-11-08 | $3.11M derived: sum of 4 quarters · filed 2023-11-08 |
| 2022-06-30 | $1.47M derived: 10-Q 6 month − 10-Q 3 month · filed 2023-08-08 | $7.93M 10-Q · filed 2023-08-08 | $7.56M derived: sum of 3 quarters · filed 2023-08-08 | $11.52M derived: sum of 4 quarters · filed 2023-08-08 |
| 2022-03-31 | $6.45M 10-Q · filed 2023-05-11 | $6.09M derived: sum of 2 quarters · filed 2023-05-11 | $10.05M derived: sum of 3 quarters · filed 2023-05-11 | $9.50M derived: sum of 4 quarters · filed 2023-05-11 |
| 2021-12-31 | -$364.00K derived: 10-K 12 month − 10-Q 9 month · filed 2023-03-23 | $3.60M derived: sum of 2 quarters · filed 2023-03-23 | $3.05M derived: sum of 3 quarters · filed 2023-03-23 | $6.82M 10-K · filed 2023-03-23 |
| 2021-09-30 | $3.96M derived: 10-Q 9 month − 10-Q 6 month · filed 2022-11-10 | $3.41M derived: sum of 2 quarters · filed 2022-11-10 | $7.18M 10-Q · filed 2022-11-10 | |
| 2021-06-30 | -$552.00K derived: 10-Q 6 month − 10-Q 3 month · filed 2022-08-12 | $3.22M 10-Q · filed 2022-08-12 | ||
| 2021-03-31 | $3.77M 10-Q · filed 2022-06-16 |
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| AN2 Therapeutics, Inc. (ANTX) | United States | $0.185B | -4.84 |
| ALX ONCOLOGY HOLDINGS INC (ALXO) | United States | $0.187B | -3.52 |
| Fortress Biotech, Inc. (FBIO) | United States | $0.188B | 0.91 |
| Organogenesis Holdings Inc. (ORGO) | United States | $0.182B | -3.70 |
| Zentalis Pharmaceuticals, Inc. (ZNTL) | United States | $0.196B | -2.48 |
| ORAMED PHARMACEUTICALS INC. (ORMP) | $0.199B | 1.13 | |
| Nkarta, Inc. (NKTX) | United States | $0.205B | -1.73 |
| Tonix Pharmaceuticals Holding Corp. (TNXP) | United States | $0.166B | -1.34 |
| Minerva Neurosciences, Inc. (NERV) | United States | $0.165B | -0.66 |
| ADC Therapeutics SA (ADCT) | $0.163B | -1.39 |